278 related articles for article (PubMed ID: 10897124)
41. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
42. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.
Straus DJ; Gaynor JJ; Myers J; Merke DP; Caravelli J; Chapman D; Yahalom J; Clarkson BD
J Clin Oncol; 1990 Jul; 8(7):1173-86. PubMed ID: 1694235
[TBL] [Abstract][Full Text] [Related]
43. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
[TBL] [Abstract][Full Text] [Related]
44. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
45. [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone].
Weiss J; von Roemeling R; Peters HD; Schmoll HJ; Diehl V
Dtsch Med Wochenschr; 1983 Sep; 108(38):1428-32. PubMed ID: 6192987
[TBL] [Abstract][Full Text] [Related]
46. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
47. Third-line chemotherapy with CAVP (CCNU, melphalan, etoposide and prednisone) in refractory Hodgkin's disease.
Cartoni C; Cimino G; Anselmo AP; Amadori S; Mandelli F
Haematologica; 1989; 74(3):273-7. PubMed ID: 2511096
[TBL] [Abstract][Full Text] [Related]
48. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
49. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
[TBL] [Abstract][Full Text] [Related]
50. [Alternating chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP); etoposide, procarbazine, vindesine and prednisolone (EPVP) as a treatment for advanced-stage Hodgkin's disease].
Kumagai K; Takagi T; Sakai C; Wakatsuki S
Gan To Kagaku Ryoho; 1996 Mar; 23(4):499-501. PubMed ID: 8678506
[No Abstract] [Full Text] [Related]
51. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
[TBL] [Abstract][Full Text] [Related]
52. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of standard treatment in patients with Hodgkin's disease--a single center experience.
Geissler K; Gisslinger H; Knöbl P; Sperr W; Valent P; Dieckmann K; Chott A; Pötter R; Lechner K; Jäger U
Wien Klin Wochenschr; 2000 Jul; 112(14):624-8. PubMed ID: 11008324
[TBL] [Abstract][Full Text] [Related]
54. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
55. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma.
Zinzani PL; Tani M; Stefoni V; Albertini P; Bendandi M; Gherlinzoni F; Alinari L; Vigna E; Tura S
Haematologica; 2001 Mar; 86(3):287-90. PubMed ID: 11255276
[TBL] [Abstract][Full Text] [Related]
57. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.
Engert A; Bredenfeld H; Döhner H; Ho AD; Schmitz N; Berger D; Bacon P; Skacel T; Easton V; Diehl V
Haematologica; 2006 Apr; 91(4):546-9. PubMed ID: 16585019
[TBL] [Abstract][Full Text] [Related]
58. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
[TBL] [Abstract][Full Text] [Related]
59. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
[TBL] [Abstract][Full Text] [Related]
60. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]